The European Commission wants to give its reputation for handling the pandemic a shot in the arm by setting up a new biopharma research funding agency and getting ahead of the curve on COVID-19 variants.
The commission has been heavily criticized within the EU's 27 member states for what has been seen as a slow and disjointed response to the COVID-19 crisis, including the procurement, regulatory
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?